Enlarged Leadership Team with CSO, Prof. Dr. Anton Wellstein, and CBO, Dr. Matthias Evers 

Hamburg, Germany – April 8, 2025 – Life Science Newswire – Indivumed is proud to announce major milestones achieved, cementing its position as a leading oncology R&D company. Its unique, patient-centric approach to precision oncology, including data-driven AI to decipher cell biology in thousands of highly standardized cancer tissue samples, has successfully passed its proof-of-concept phase. Numerous therapeutically novel targets and the first prototype compounds are presented, promising to significantly advance drug development in oncology. Indivumed has expanded its leadership team with Prof. Dr. Anton Wellstein as Chief Scientific Officer (CSO) and Dr. Matthias Evers as Chief Business Officer (CBO) to drive the continued growth of the company.

Unique Approach and Unmatched Data Quality
Indivumed’s unique patient-centric R&D approach to cancer research is driven by a standardized collection process with a cold ischemia time of under 10 minutes, ensuring the integrity of tissue samples and preserving therapeutic target expression. The resulting database, IndivuType, is built on over 20 years of global clinical collaboration. It combines comprehensive multi-omics including proteomics and phospho-proteomics, and longitudinal clinical data, providing unparalleled molecular insights that are critical for oncology drug discovery.

Building on a Legacy of Excellence
IndivuType is the foundation of Indivumed’s data-driven target identification and validation process. By utilizing advanced data analytics and AI algorithms Indivumed creates a holistic view of deep and multi-modal molecular data to discover therapeutically novel targets. In addition, in-house generated patient-derived 2D and 3D cellular models, closely mimicking original tumor biology, enable effective validation of targets and reduce risk in downstream drug development.

Drug discovery activities and collaborations encompass virtual and fragment-based ligand screening, hit and lead optimization, and preclinical development, aiming to advance promising candidates toward IND. In-depth knowledge of the molecular and clinical characteristics of the targeted patient population further enables the company to support tailor-made clinical trial and patient stratification strategies at an early stage.

Deep insights leading to therapeutically novel targets
The current R&D focus lies on colorectal cancer, a disease with a high unmet medical need. Indivumed’s pipeline includes a range of targets in different stages of validation and drug discovery. Discussions with potential pharmaceutical partners are ongoing to develop hit/lead molecules towards IND and into valuable precision therapeutics.

“Our targets will have a huge impact on future cancer treatments. We have come a long way to make our vision a reality,” says Founder and CEO Prof. Dr. Hartmut Juhl, continuing “we collaborate with pharmaceutical and biotech companies to further develop our novel and promising drug targets toward innovative cancer therapies, through co-development and special tailored collaborations. CRC is our focus now, but our unique biobank and database gives us the opportunity to start programs in further indications such as NSCLC, breast cancer, and more.”

Extended Management Team for Development Success
The company recently welcomed two new members to the management team. Prof. Dr. Anton Wellstein, renowned pharmacology professor at the Lombardi Comprehensive Cancer Center, acts as Chief Scientific Officer. With over 200 peer-reviewed publications and numerous prestigious awards, Prof. Dr. Wellstein’s expertise will further strengthen the company’s commitment to pioneering precision oncology.

“Indivumed’s R&D approach brings novel insights through our unique starting point. Carefully collected and curated patient samples are excellent representations of the characteristic features of the disease, making the difference in target discovery and lead generation towards innovative and successful therapeutics,” said Prof. Dr. Anton Wellstein.

Indivumed is also pleased to announce that Dr. Matthias Evers has joined the company as Chief Business Officer as of April. With a distinguished career in biopharma R&D, Dr. Evers brings a rare combination of scientific depth and strategic business leadership. His academic background in biochemistry, molecular biology, and bioinformatics, coupled with his global leadership experience – most recently at McKinsey & Company and Evotec – strengthens Indivumed’s position at a pivotal time in its development.

Dr. Evers commented: “Unmet needs in oncology continue to grow, and the true bottleneck today lies in deep disease understanding and the identification of novel targets. Having spent many years advancing new discovery models and approaches for a deeper understanding of disease biology, I believe Indivumed offers something truly unique – as a strategic partner to pharma companies and, most importantly, as a source of hope for patients in need of next-generation therapies.” 

About Indivumed:
Indivumed is a biotech company focused on precision oncology. We discover therapeutically novel targets for the development of precision cancer therapeutics and strive for a future in which every cancer patient can benefit from precise therapeutic treatments.

To achieve this goal, we dedicate our skills and knowledge in cancer research to the identification, validation, and preclinical development of first-in-class therapeutics. With more than twenty years of experience and a truly unique resource, based on a standardized collection process that secures a cold ischemia time of under 10 minutes, we are committed to transforming oncology and bringing the best possible therapies to patients.

www.indivumed.com